Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7456 to 7470 of 7686 results

  1. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    Discontinued [GID-TA10502]

    Technology appraisal guidance
    Discontinued

  2. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    Discontinued [GID-TA11255]

    Technology appraisal guidance
    Discontinued

  3. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    Discontinued [GID-TA10929]

    Technology appraisal guidance
    Discontinued

  4. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued [GID-TA11204]

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]

    Discontinued [GID-TA10848]

    Technology appraisal guidance
    Discontinued

  6. Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]

    Discontinued [GID-TA10861]

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]

    Discontinued [GID-TA10880]

    Technology appraisal guidance
    Discontinued

  8. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]

    In development [GID-TA11014] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development [GID-TA11015] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    In development [GID-TA11093] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development [GID-TA10568] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Atrial fibrillation - ximelagatran [ID376]

    Discontinued [GID-TAG377]

    Technology appraisal guidance
    Discontinued

  13. Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) (TA869)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1015.

    Technology appraisal guidance
    Published
    16 February 2023

  14. Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer (IPG614)

    This guidance has been updated and replaced by NICE interventional procedures guidance 794.

    Interventional procedures guidance
    Published
    23 May 2018

  15. Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

    This guidance has been replaced by NICE guideline NG17.

    Technology appraisal guidance
    Last updated
    1 August 2015